Rural development department workers stage wait-in protest
The protestors, led by S. Edwin, district president of the Union, district and block-level coordinators should be appointed on permanent basis so that monitoring and follow-up of the works would become easier. The Tamil Nadu Government, as promised, should give the incentive to all workers involved in COVID prevention activities. The district and the block-level coordinators and the computer operators should be given annual increments.
Gratuity should be given to all temporary workers and all vacancies in the village panchayats filled-up. Minimum wages should be fixed as per law and given to the sanitary workers, motivators, pump operators, overhead tank operators and computer operators. Social security schemes like Employees' State Insurance, Provident Fund etc. should be extended to these workers, they said.
State coordinator of the Union S. Govindan, state joint secretary V. Paramasivan, state president of AITUC S. Kasi Viswanathan and others spoke.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
23 minutes ago
- Economic Times
Amit Shah's explosive Rajya Sabha address: 7 key moments when the HM dug at the Opposition
In a fiery Lok Sabha address during the Monsoon Session, Union Home Minister Amit Shah launched a scathing attack on the Opposition, especially targeting the Congress over national security, terrorism, and PoK. Highlighting seven key moments, Shah invoked incidents like the Batla House encounter, 26/11, and boldly declared BJP's intent to reclaim Pakistan-occupied Kashmir. Show more 07:04 12:12 04:17 08:01 08:24 09:18 01:39 01:14:54 28:24 34:32 05:44 07:21 06:03 35:30 01:44 01:15 10:35 04:34 03:15 55:27 03:02 01:56 05:01 03:26 03:01 04:27 03:54 03:07 12:45
&w=3840&q=100)

Business Standard
23 minutes ago
- Business Standard
LIVE news updates: India has to now contend with China, America, Pakistan, says Congress
After US President Donald Trump imposed a 25 per cent tariff on India, the Congress on Thursday criticised Prime Minister Narendra Modi, noting that while he had earlier highlighted issues related to TOP — Tomato, Onion, Potato — price fluctuations, the nation was now facing political challenges stemming from CAP — China, America, Pakistan. The opposition party said that on the one hand President Trump criticises India strongly and imposes penalties on it for trading with Russia, while on the other hand, just before the Iranian President's visit to Pakistan, he announces a big partnership with Pakistan for hydrocarbon exploration and development, alongside a trade deal. Union Minister for Ports, Shipping and Waterways, Sarbananda Sonowal, is set to move the Merchant Shipping Bill, 2024 in the Lok Sabha for its passage. The proposed legislation seeks to modernise and unify existing shipping laws to bring them in line with international maritime treaties to which India is a signatory. As per the list of business in the Lower House, the bill aims to consolidate and revise merchant shipping laws to ensure India meets its international maritime obligations. It also seeks to support the growth of Indian shipping and ensure the effective management of the country's mercantile marine in alignment with national interests. 11:13 AM India has to now contend with China, America, Pakistan, says Congress After US President Donald Trump announced a 25 per cent tariff on India, the Congress on Thursday took a swipe at Prime Minister Narendra Modi, saying that he once spoke of the TOP -- Tomato, Onion, Potato -- challenges in prices, but the country now has to contend with the political challenges arising out of CAP -China, America, Pakistan.


India Today
36 minutes ago
- India Today
Top US vaccine official Vinay Prasad leaves agency 3 months after being appointed
The US Food and Drug Administration's (FDA) top vaccine official, Vinay Prasad, has left the agency after just three months as Director of the Centre for Biologics Evaluation and Research, a government spokesperson an oncologist who was a fierce critic of the US COVID-19 vaccine and mask mandates, was appointed in May by FDA Commissioner Marty Makary. Together they promised to speed regulatory action and pilot new review recent days, criticism of Prasad's tenure has intensified around the agency's handling of a gene therapy for Duchenne muscular dystrophy from Sarepta Therapeutics. The FDA-approved therapy played a role in the death of two teens who had advanced disease, and after a third death in a separate experimental gene therapy from the company, the FDA on July 18 asked Sarepta to stop all shipments of the approved DMD therapy, saying it had safety Loomer, a far-right activist and President Donald Trump ally, on July 20 posted a blog in which she called Prasad a "progressive leftist saboteur" who was undermining the agency's work. Loomer's critiques earlier this year led to the ouster of national security Monday, the Wall Street Journal's opinion section ran two pieces criticising Prasad, one of which called him a Bernie Sanders acolyte in MAHA drag, referring to the Trump administration's "Make America Healthy Again" movement. Both said he was not basing regulatory decisions on whether drugs helped patients, but on price."When he saw some of these sort of smear pieces, he didn't want to be a distraction," Makary said of Prasad's departure in an interview with CNBC on Tidmarsh, a former pharmaceutical executive who was recently appointed to lead the FDA's Center for Drug Evaluation and Research (CBER), will also be the acting CBER director, according to the agency's Department of Health and Human Services, which oversees the FDA, did not announce when the role would be permanently whose departure was announced late on Tuesday, did not immediately respond to a request for FDA on Monday changed course on Sarepta and said shipments to the main group of patients for the drug could changes under Prasad, who was also the agency's chief medical and science officer, included a new policy limiting the approval of COVID-19 vaccines, and his FDA division also rejected therapies from Replimmune and Capricor of Replimmune nearly doubled in value, while those of Sarepta and Capricor gained 11% and 18%, respectively, on and STAT news first reported Prasad's was a physician who joined the agency from the University of California, San Francisco. He has had stints at the National Cancer Institute and the National Institutes of FDA and other health agencies have seen multiple shakeups in recent months, under the leadership of US Health Secretary Robert F. Kennedy predecessor and long-time vaccine official at the FDA, Peter Marks, was ousted earlier this year, followed by gene therapy head Nicole Verdun."While another vacancy and another potential new face add uncertainty, we still think Prasad's departure is a net positive for the sector as many of our conversations have been overwhelmingly focused on regulatory risk and what he may or may not do," said Leerink analyst Joseph Schwartz.- EndsMust Watch IN THIS STORY#Donald Trump#White House#Covid-19